product name TCID
Description: TCID is a DUB inhibitor for ubiquitin C-terminal hydrolase L3 with IC50 of 0.6 μM, 125-fold selective to L1. GlyT2 ubiquitination was diminished by inhibition of UCHL3 with TCID (10 μm) and inhibition of UCHL1 with LDN-57444 (10 μm) in brainstem and spinal cord primary neurons, and the effect was more significant when cell was treated with the inhibitors for a prolonged period. In transfected MDCK cells, TCID (10 μm for 30 mins) was not able to affect the UCH-L1 inhibitor promoted accumulation of YFP-GLT-1 in intracellular vesicles.
References: Chem Biol. 2003 Sep;10(9):837-46; Glia. 2012 Sep;60(9):1356-65.
283.92
Formula
C9H2Cl4O2
CAS No.
30675-13-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 23 mg/mL (81.0 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19415165
| In Vitro |
In vitro activity: TCID is selective for UCH-L3 over UCH-L1 by over 100-fold. NU6027 (10 μM) does not promote YFP-GLT-1 accumulation in intracellular vesicles in transfected MDCK cells, while LDN-57444 (10 μM) promotes YFP-GLT-1 accumulation. NU6027 (10 μM) does not produce long-term lysosomal degradation of GLT-1, while LDN-57444 (10 μM) has such effect. TCID (10 μM) diminishes GlyT2 ubiquitination in brainstem and spinal cord primary neurons, which is more pronounced when UCHL1 is inhibited and when cells are exposed to these inhibitors for longer periods. Kinase Assay: Cell Assay: In transfected MDCK cells, TCID (10 μm for 30 mins) was not able to affect the UCH-L1 inhibitor promoted accumulation of YFP-GLT-1 in intracellular vesicles. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Chem Biol. 2003 Sep;10(9):837-46; Glia. 2012 Sep;60(9):1356-65. |
